Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Breast (Edinburgh, Scotland)
|
October 25, 2012
Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature
Kimberly A Boswell, Xufang Wang, Manasee V Shah, et al.
European Journal of Haematology
|
July 21, 2021
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
James D Griffin, Yan Song, Hongbo Yang, et al.
Journal of Medical Economics
|
December 7, 2020
A budget impact analysis of gilteritinib for the treatment of relapsed or refractory <i>FLT3</i> <sup>mut+</sup> acute myeloid leukemia in a US health plan
Bhavik J Pandya, Hongbo Yang, Cynthia Schmeichel, et al.
European Journal of Haematology
|
December 23, 2018
Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study
James D Griffin, Hongbo Yang, Yan Song, et al.
Leukemia & Lymphoma
|
November 9, 2021
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
Amer M Zeidan, Cynthia Z Qi, Hongbo Yang, et al.
Journal of Managed Care & Specialty Pharmacy
|
October 1, 2021
Cost-effectiveness of gilteritinib for relapsed/refractory <i>FLT3</i><sup>mut+</sup> acute myeloid leukemia
Bhavik J Pandya, Cynthia Z Qi, Andy Garnham, et al.
Advances in Therapy
|
December 13, 2016
Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain
Brett A Maiese, An T Pham, Manasee V Shah, et al.
Leukemia & Lymphoma
|
April 5, 2023
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with <i>FLT3</i>-mutated relapsed/refractory AML
Ellen K Ritchie, David Cella, Francesco Fabbiano, et al.
Leukemia & Lymphoma
|
June 9, 2023
The experience of patients with acute myeloid leukemia in remission post-transplant
David Cella, Kimberly Kelly, Anna de la Motte, et al.
Patient Preference and Adherence
|
November 13, 2023
Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation
Lalit Saini, James D Griffin, Bhavik J Pandya, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Breast (Edinburgh, Scotland)
|
October 25, 2012
Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature
Kimberly A Boswell, Xufang Wang, Manasee V Shah, et al.
European Journal of Haematology
|
July 21, 2021
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
James D Griffin, Yan Song, Hongbo Yang, et al.
Journal of Medical Economics
|
December 7, 2020
A budget impact analysis of gilteritinib for the treatment of relapsed or refractory <i>FLT3</i> <sup>mut+</sup> acute myeloid leukemia in a US health plan
Bhavik J Pandya, Hongbo Yang, Cynthia Schmeichel, et al.
European Journal of Haematology
|
December 23, 2018
Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study
James D Griffin, Hongbo Yang, Yan Song, et al.
Leukemia & Lymphoma
|
November 9, 2021
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
Amer M Zeidan, Cynthia Z Qi, Hongbo Yang, et al.
Journal of Managed Care & Specialty Pharmacy
|
October 1, 2021
Cost-effectiveness of gilteritinib for relapsed/refractory <i>FLT3</i><sup>mut+</sup> acute myeloid leukemia
Bhavik J Pandya, Cynthia Z Qi, Andy Garnham, et al.
Advances in Therapy
|
December 13, 2016
Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain
Brett A Maiese, An T Pham, Manasee V Shah, et al.
Leukemia & Lymphoma
|
April 5, 2023
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with <i>FLT3</i>-mutated relapsed/refractory AML
Ellen K Ritchie, David Cella, Francesco Fabbiano, et al.
Leukemia & Lymphoma
|
June 9, 2023
The experience of patients with acute myeloid leukemia in remission post-transplant
David Cella, Kimberly Kelly, Anna de la Motte, et al.
Patient Preference and Adherence
|
November 13, 2023
Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation
Lalit Saini, James D Griffin, Bhavik J Pandya, et al.
Page
of 2